A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines

Clinical trial NCT05030311 · COMPLETED

Trial details

NCT number: NCT05030311
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Spontaneous Urticaria

Start date: 2021-11-30
Primary completion: 2023-12-27
Enrollment: 470

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.